The author's findings establish that the commonly inactivated tumor suppressor Smad4 is a critical regulator of pancreatic ductal adenocarcinoma tumor immunogenicity by activating cancer‐autonomous DNA sensing signaling, and suggest a potential role of Smad4 expression as a biomarker in developing future effective immunotherapy for PDACs. Here, SMAD4 is linked to neoplasm.